Field Reimbursement Director

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

The Field Reimbursement Director (FRD) plays a crucial role in ensuring timely access to ziftomenib for patients after they have been prescribed. This position is responsible for working directly with healthcare providers, payers, Kura’s distribution partners and other stakeholders to overcome reimbursement barriers. The FRD will ensure that patients have access to necessary treatments while facilitating seamless reimbursement processes in a complex healthcare environment.

• Leadership and Team Management:
• Work collaboratively with Kura field leadership to define clear roles & responsibilities and ways of working
• Assist Kura’s training team to develop appropriate Reimbursement and Access training for the Kura field sales team
• Work closely with Kura’s access and distribution operations director to identify process improvements.
• Reimbursement Support:
• Lead reimbursement support for healthcare providers and patients, addressing and resolving payer-related issues and reimbursement obstacles.
• Serve as the subject matter expert (SME) for all payer policies, coding, and billing requirements specific to Kura’s product portfolio.
• Assist healthcare providers in navigating the reimbursement process, ensuring that claims are filed timely.
• Work compliantly with fulfilling pharmacy to quickly identify and resolve access barriers
• Strategic Collaboration:
• Collaborate cross-functionally with market access, sales, legal, and compliance teams to ensure alignment in field strategies.
• Work closely with payer and provider accounts to manage and resolve reimbursement issues, including prior authorization, denials, and appeals.
• Provide input and recommendations on payer policy changes, trends, and regulations to inform business decisions.
• Lead without authority to ensure the field sales team has the information and resources available to be effective account managers to their customers
• Stakeholder Engagement:
• Build and maintain strong relationships with key external stakeholders, including payers, healthcare providers, and third-party vendors.
• Serve as a key point of contact for field-based reimbursement issues and inquiries, facilitating communication between internal teams and external partners.
• Coaching field sales teams on front line reimbursement problem solving skills.
• Reporting and Documentation:
• Maintain compliant records of reimbursement interactions, outcomes, and follow-up actions.
• Provide regular updates and reports to senior management on reimbursement trends, challenges, and the impact on product access.
• Ensure that all activities comply with regulatory requirements and corporate policies.
• Market Intelligence:
• Monitor reimbursement trends, payer policy changes, and market dynamics to ensure proactive solutions and strategies.
• Support the development of educational materials and training programs for internal and external stakeholders on reimbursement topics.

JOB SPECIFICATIONS:

• Education:
• Bachelor’s degree in Business, Healthcare Administration, Pharmacy, Nursing, or a related field. Advanced degree (MBA, MS, or other) preferred.
• Experience:
• At least 15+ years of experience in reimbursement, market access, or related areas within the healthcare industry, with a focus on Oncology.
• Experience building functionality/ capability in a fast-paced environment.
• In-depth knowledge of payer systems, reimbursement processes, and healthcare regulations (e.g., CMS, Medicaid, commercial payers).
• Proven success in overcoming reimbursement barriers and facilitating patient access to therapies.
• Experience managing teams, preferably field reimbursement or managed care/ reimbursement related
• Skills & Competencies:
• Strong leadership skills with a proven ability to manage, coach, and motivate a team.
• Excellent communication skills, both verbal and written, with the ability to interact effectively with senior management, healthcare providers, and external partners.
• Analytical mindset with the ability to interpret reimbursement data and trends.
• Strong problem-solving and negotiation skills.
• Ability to work independently and manage multiple priorities in a dynamic environment.
• Technical Proficiency:
• Proficient in Microsoft Office Suite (Word, Excel, PowerPoint, Outlook).
• capable of learning/ using custom software used to track patient journey insights.

• Additional Information:
  • Travel requirements: 60 % travel anticipated
  • This position may require working outside of traditional business hours, depending on the needs of the market.

The base range for a Director is $210,000 - $246,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.